Virbac Logo

Virbac

Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.

FR000 | PA

Overview

Corporate Details

ISIN(s):
FR0000031577
LEI:
969500QQ1X5XHG649644
Country:
France
Address:
1ERE AVENUE, 06510 CARROS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Founded in 1968 by a veterinarian, the company develops, manufactures, and distributes a comprehensive range of products and services for veterinarians, farmers, and pet owners. Operating in over 100 countries, its portfolio offers innovative solutions covering the majority of animal species and diseases. Key product areas include pharmaceuticals, vaccines, parasite control, dental care, nutritional supplements, and diagnostic tools, all aimed at shaping the future of animal health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 17:45
Earnings Release
VIRBAC: résultats semestriels 2025
French 1.2 MB
2025-09-12 17:45
Earnings Release
Virbac: 2025 Half-year results
English 1.1 MB
2025-09-12 17:30
Interim Report
Virbac : Rapport financier semestriel 2025
French 13.2 MB
2025-09-12 17:30
Interim Report
Virbac : Half-yearly financial report 2025
English 13.4 MB
2025-09-12 17:30
Report Publication Announcement
Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30…
French 264.9 KB
2025-09-12 17:30
Report Publication Announcement
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
English 264.6 KB
2025-08-18 09:30
Remuneration Information
VIRBAC: Informations sur les conditions de rémunération de Paul Martingell
French 80.5 KB
2025-08-18 09:30
Remuneration Information
Virbac:: Paul Martingell's compensation terms
English 128.7 KB
2025-06-19 08:30
Board/Management Information
VIRBAC: Paul Martingell nommé directeur général du groupe Virbac au 1er septemb…
French 271.7 KB
2025-06-19 08:30
Board/Management Information
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effecti…
English 279.3 KB
2025-06-10 09:59
Declaration of Voting Results & Voting Rights Announcements
Virbac : Declaration of the number of share and voting rights 05/2025
English 59.2 KB
2025-06-10 09:59
Declaration of Voting Results & Voting Rights Announcements
Virbac : Déclaration d'actions et de droits de vote 05/2025
French 36.6 KB
2025-05-26 10:05
Pre-Annual General Meeting Information
VIRBAC: Communiqué précisant les modalités de mise à disposition ou de consulta…
French 26.3 KB
2025-05-07 16:27
Declaration of Voting Results & Voting Rights Announcements
Virbac : Déclaration d'actions et de droits de vote 04/2025
French 36.6 KB
2025-04-28 19:00
Annual Report (ESEF)
Virbac : Rapport Annuel Virbac au 31 décembre 2024 (ESEF)
French 22.1 MB

Automate Your Workflow. Get a real-time feed of all Virbac filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Virbac via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-17 N/A Other Sell 370 135,790.00 EUR
2023-07-19 N/A Other Buy 950 245,100.00 EUR

Peer Companies

Company Country Ticker View
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea 471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan 7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan 4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea 068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland CLN
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark CESSA
CG Invites Co., Ltd. Logo
Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.
South Korea 083790
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
South Korea 261780
Manufactures veterinary medicines and feed additives for livestock, aquatic animals, and pets.
South Korea 052670
Chemical Works of Gedeon Richter Plc Logo
Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.
Hungary RICHT

Talk to a Data Expert

Have a question? We'll get back to you promptly.